Metrics to compare | ALNFL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALNFLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.2x | −2.5x | −0.3x | |
PEG Ratio | 0.09 | −0.03 | 0.00 | |
Price/Book | 23.6x | 0.5x | 2.6x | |
Price / LTM Sales | 38,421.2x | 6.8x | 2.9x | |
Upside (Analyst Target) | - | 223.4% | 63.9% | |
Fair Value Upside | Unlock | −4.4% | 9.4% | Unlock |
NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and is headquartered in Castelnau-le-Lez, France.